logo
Plus   Neg
Share
Email
Comment

AMAG Pharma Says Ferumoxytol Gets European Marketing Authorization To Treat IDA

AMAG Pharmaceuticals Inc. (AMAG) announced that the European Commission has granted marketing authorization for ferumoxytol, an intravenous or IV iron therapy to treat iron deficiency anemia or IDA in adult patients with chronic kidney disease or CKD.

The company said that the marketing authorization followed a positive opinion, issued on April 19, 2012, by the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency.

Ferumoxytol was approved for the same indication in the US under the brand name Feraheme in June 2009.

The company said that the marketing authorization is valid in the current European Union Member States as well as in Iceland and Norway, and is based on data obtained from an extensive clinical development program. Takeda Pharmaceutical Company Limited, AMAG's partner in Europe, plans to launch ferumoxytol in Europe under the brand name Rienso in 2012.

The company also said that the EU marketing authorization triggers a $15 million milestone payment to AMAG from Takeda; the first commercial sale of Riensoin Europe will trigger another $15 million milestone payment to AMAG. Additionally, AMAG is entitled to receive tiered, double-digit royalties on sales of Rienso in the licensed territories.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
HP Inc. (HPQ), the PC and printer business of the former Hewlett-Packard Co., on Thursday reported a profit for the first quarter that increased from last year and trumped analysts' expectations driven largely by a higher-than-expected revenues. The PC giant detailed a second-quarter and full year... Hormel Foods Corp. (HRL) reported a profit for the first quarter of fiscal 2018 that increased 28.9 percent from the prior year. Total net sales grew 2.2 percent from last year. Earnings per share topped analysts' expectations, while quarterly revenues missed their estimates. The company raised annual earnings per share guidance due to U.S. tax reform, while it maintained annual net sales outlook. Shares of Deutsche Telekom AG were losing around 3 percent in the morning trading in Germany after the telecom giant reported Thursday a decline in fourth-quarter EBITDA, a key earnings metric, with weak revenues. However, the company recorded a net profit, compared to loss last year on positive US tax effect. Deutsche Telekom lifted its dividend and said it expects higher earnings in 2018.
comments powered by Disqus
Follow RTT